DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: lansoprazole

Summary for Generic Name: lansoprazole

Tradenames:7
Patents:5
Applicants:15
NDAs:20
Drug Master File Entries: see list48
Suppliers: see list9
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: lansoprazole

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors

Clinical Trials for: lansoprazole

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
Status: Completed Condition: Esophagitis; Reflux

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Status: Completed Condition: Healthy

The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes
Status: Not yet recruiting Condition: Type 1 Diabetes

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
Status: Completed Condition: Frequent Heartburn

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Status: Completed Condition: Heartburn; Gastroesophageal Reflux Disease

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain
Status: Withdrawn Condition: Chest Pain; Gastrointestinal Reflux Disease

The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients
Status: Not yet recruiting Condition: Type 1 Diabetes

Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Dr Reddys Labs Ltd
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL091269Oct 15, 2010RXNo<disabled>
Dr Reddys Labs Ltd
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL202194May 18, 2012OTCNo<disabled>
Mylan Pharms Inc
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL090763Nov 10, 2009RXNo<disabled>
Natco Pharma Ltd
LANSOPRAZOLE
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL201921Dec 18, 2012RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc